Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

Global Plasma Protease C1-Inhibitor Market is valued approximately USD 3752.3 million in 2023 and is anticipated to grow with a healthy growth rate of more than 17.72% over the forecast period ...